Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
doi: 10.1111/j.0105-2896.2009.00859.x 188 BeyerKLieSABjorndalBBergeRKSvardalABrunJGet al
Bo v da bng kem chng nng na nh
Referanslar: 1
A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
US$ 29.83
US$ 28.32
US$ 20.84
US$ 23.57
US$ 28.85
US$ 25.44
